All In Biotech

Drug Trial Radar · NCT03676140

Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )

A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases

Last checked: Nov 19, 2026Latest source record: Feb 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 20,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,000

Actual

Start

Oct 1, 2018

Primary completion

Dec 15, 2018

Study completion Jan 1, 2019

Sponsor

Lead sponsor
Lihir Medical CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
London School of Hygiene and Tropical Medicine
First posted
Sep 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF. Treatment will be provided as a single dose Mass Drug Administration (MDA) to the whole community. Communities will be randomised to receive either treatment with IDA and Azithromycin on the same day or separately. Active monitoring for adverse events will be conducted and the frequency of adverse events compared between individuals receiving combined MDA or separate MDA.

Conditions

  • Trachoma
  • Yaws
  • Lymphatic Filariases
  • Scabies
  • Strongyloidiasis

Interventions

  • Albendazole on Day 1Drug

    Albendazole 400 mg oral tablet Single Dose Treatment on D1

  • Ivermectin on Day 1Drug

    Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1

  • Diethylcarbamazine on day 1Drug

    Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1

  • Azithromycin on Day 1Drug

    Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1

  • Azithromycin on Day 8Drug

    Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Self Reported Adverse EventTime frame: 7 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Namatanai Hospital

    Namatanai, Papua New Guinea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.